{
    "id": 25852,
    "fullName": "PTK6 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PTK6 positive indicates the presence of the PTK6 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5753,
        "geneSymbol": "PTK6",
        "terms": [
            "PTK6",
            "BRK"
        ]
    },
    "variant": "positive",
    "createDate": "01/03/2017",
    "updateDate": "01/03/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9678,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XMU-MP-2 inhibited PTK6 downstream signaling and proliferation and increased apoptosis in PTK6-expressing breast cancer cell lines in culture, and reduced tumor growth in a PTK6-expressing breast cancer cell line xenograft model (PMID: 27758886).",
            "molecularProfile": {
                "id": 26967,
                "profileName": "PTK6 positive"
            },
            "therapy": {
                "id": 5154,
                "therapyName": "XMU-MP-2",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7466,
                    "pubMedId": 27758886,
                    "title": "Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27758886"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9683,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Afimoxifene (4-hydroxy-tamoxifen) and XMU-MP-2 demonstrated synergy in inhibiting growth of a breast cancer cell line with ESR1 (ER) and PTK6 expression in culture (PMID: 27758886).",
            "molecularProfile": {
                "id": 26973,
                "profileName": "ESR1 pos PTK6 pos"
            },
            "therapy": {
                "id": 5158,
                "therapyName": "Afimoxifene + XMU-MP-2",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7466,
                    "pubMedId": 27758886,
                    "title": "Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27758886"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26967,
            "profileName": "PTK6 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26973,
            "profileName": "ESR1 pos PTK6 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}